Suzanne E. Schindler
@suzanneeschindler.bsky.social
Clinical neurologist and neuroscientist dedicated to improving the diagnosis and treatment of dementia.
Reposted by Suzanne E. Schindler
ICYMI: New online! Towards pharmacological prevention of Alzheimer disease
Towards pharmacological prevention of Alzheimer disease
Nature Reviews Neurology, Published online: 03 November 2025; doi:10.1038/s41582-025-01154-yAdvances in biomarkers, blood tests and disease-modifying therapies have created a credible path to clinical prevention of Alzheimer disease (AD). In this Perspective, the authors discuss promising approaches to the prevention of AD and highlight strategic gaps.
bit.ly
November 10, 2025 at 4:04 AM
ICYMI: New online! Towards pharmacological prevention of Alzheimer disease
Reposted by Suzanne E. Schindler
That's exactly why Randall J. Bateman, MD, was invited to
@cbssundaymorning.bsky.social — see how our groundbreaking clinical trials could change the outcome for millions of people who live in fear of what Alzheimer’s takes from them: campaigns.med.washu.edu/alz
@cbssundaymorning.bsky.social — see how our groundbreaking clinical trials could change the outcome for millions of people who live in fear of what Alzheimer’s takes from them: campaigns.med.washu.edu/alz
November 9, 2025 at 4:10 PM
That's exactly why Randall J. Bateman, MD, was invited to
@cbssundaymorning.bsky.social — see how our groundbreaking clinical trials could change the outcome for millions of people who live in fear of what Alzheimer’s takes from them: campaigns.med.washu.edu/alz
@cbssundaymorning.bsky.social — see how our groundbreaking clinical trials could change the outcome for millions of people who live in fear of what Alzheimer’s takes from them: campaigns.med.washu.edu/alz
Reposted by Suzanne E. Schindler
The FDA has cleared the first blood test for Alzheimer’s for use in primary care settings to rule out the presence of amyloid.
“This is another important step toward expanding access to Alzheimer’s diagnostic tools." -Joanne Pike, Association president & CEO
Read our full statement: bit.ly/4oh3Tiu
“This is another important step toward expanding access to Alzheimer’s diagnostic tools." -Joanne Pike, Association president & CEO
Read our full statement: bit.ly/4oh3Tiu
Alzheimer’s Association Welcomes FDA Clearance of First Blood Test for Use in Primary Care to Rule Out Alzheimer’s-Related Amyloid Pathology
Developed by Roche, this is the first blood test for use in primary care to rule out Alzheimer's-related amyloid pathology.
www.alz.org
October 13, 2025 at 9:14 PM
The FDA has cleared the first blood test for Alzheimer’s for use in primary care settings to rule out the presence of amyloid.
“This is another important step toward expanding access to Alzheimer’s diagnostic tools." -Joanne Pike, Association president & CEO
Read our full statement: bit.ly/4oh3Tiu
“This is another important step toward expanding access to Alzheimer’s diagnostic tools." -Joanne Pike, Association president & CEO
Read our full statement: bit.ly/4oh3Tiu
Reposted by Suzanne E. Schindler
My op-ed just came out discussing how NIH leadership is failing early career researchers and, importantly, how we can push back and take our future into our own hands.
NIH Leadership Is Failing Early Career Researchers
Halted training programs, funding chaos, and hiring freezes jeopardize advancement options for early career researchers.
www.the-scientist.com
October 10, 2025 at 11:23 AM
My op-ed just came out discussing how NIH leadership is failing early career researchers and, importantly, how we can push back and take our future into our own hands.
Reposted by Suzanne E. Schindler
Has your research funding been cut by the administration? Now is the time to raise your voices. I know we all know someone, even if we ourselves haven’t been personally affected (yet). Please share your story with @nytimes.com
www.nytimes.com/2025/10/08/c...
www.nytimes.com/2025/10/08/c...
Has Your Scientific Work Been Cut? We Want to Hear.
www.nytimes.com
October 12, 2025 at 12:28 PM
Has your research funding been cut by the administration? Now is the time to raise your voices. I know we all know someone, even if we ourselves haven’t been personally affected (yet). Please share your story with @nytimes.com
www.nytimes.com/2025/10/08/c...
www.nytimes.com/2025/10/08/c...
Reposted by Suzanne E. Schindler
New landscape of the diagnosis of Alzheimer's disease www.thelancet.com/journals/lan... by @thelancet.com
#Alzheimers #dementia #biomarkers #neuroscience #NeuroSkyence
#Alzheimers #dementia #biomarkers #neuroscience #NeuroSkyence
New landscape of the diagnosis of Alzheimer's disease
Alzheimer's disease involves a drastic departure from the cognitive, functional, and
behavioural trajectory of normal ageing, and is both a dreaded and highly prevalent
cause of disability to individu...
www.thelancet.com
September 23, 2025 at 7:25 PM
New landscape of the diagnosis of Alzheimer's disease www.thelancet.com/journals/lan... by @thelancet.com
#Alzheimers #dementia #biomarkers #neuroscience #NeuroSkyence
#Alzheimers #dementia #biomarkers #neuroscience #NeuroSkyence
Review of Alzheimer's diagnostics from The Lancet:
New landscape of the diagnosis of Alzheimer's disease
www.sciencedirect.com/science/arti...
#ENDALZ
New landscape of the diagnosis of Alzheimer's disease
www.sciencedirect.com/science/arti...
#ENDALZ
September 22, 2025 at 11:49 PM
Review of Alzheimer's diagnostics from The Lancet:
New landscape of the diagnosis of Alzheimer's disease
www.sciencedirect.com/science/arti...
#ENDALZ
New landscape of the diagnosis of Alzheimer's disease
www.sciencedirect.com/science/arti...
#ENDALZ
Reposted by Suzanne E. Schindler
We're proud to share that over the last year, we invested $112.2 million in our research programs—the largest single-year on record—bringing our total active & committed investments to over $450 million. Help us continue the momentum: alz.org/donate. #ENDALZ #BrainHealth
September 19, 2025 at 2:35 PM
We're proud to share that over the last year, we invested $112.2 million in our research programs—the largest single-year on record—bringing our total active & committed investments to over $450 million. Help us continue the momentum: alz.org/donate. #ENDALZ #BrainHealth
Reposted by Suzanne E. Schindler
New paper from the lab. First author @mwelhaf.bsky.social, now in a TT position at North Carolina A&T. We wanted to know how environmental contexts and self-reported distractions impacted cognitive #EMA in older adults. mhealth.jmir.org/2025/1/e71578 1/n
Impacts of Environmental Distractions and Interruptions on Unsupervised Digital Cognitive Assessments in Older Adults: Cognitive Ecological Momentary Assessment Study
Background: Unsupervised cognitive assessments are becoming commonly used in studies of aging and neurodegenerative diseases. Because assessments are completed in everyday environments and without a p...
mhealth.jmir.org
September 13, 2025 at 1:55 PM
New paper from the lab. First author @mwelhaf.bsky.social, now in a TT position at North Carolina A&T. We wanted to know how environmental contexts and self-reported distractions impacted cognitive #EMA in older adults. mhealth.jmir.org/2025/1/e71578 1/n
"Clocks" that relate amyloid and tau PET to time were used to examine the timing of biomarker changes (including plasma biomarkers) in Alzheimer disease. Plasma Aβ42/40 changes very early! onlinelibrary.wiley.com/doi/10.1002/...
#ENDALZ
#ENDALZ
Timing of Changes in Alzheimer's Disease Plasma Biomarkers as Assessed by Amyloid and Tau PET Clocks
Objective
The objective of this study was to evaluate the timing of change of Alzheimer's disease (AD) plasma biomarkers (Aβ42/Aβ40, p-tau217, p-tau181, GFAP, and NfL) from six different assay platf.....
onlinelibrary.wiley.com
July 14, 2025 at 3:15 PM
"Clocks" that relate amyloid and tau PET to time were used to examine the timing of biomarker changes (including plasma biomarkers) in Alzheimer disease. Plasma Aβ42/40 changes very early! onlinelibrary.wiley.com/doi/10.1002/...
#ENDALZ
#ENDALZ
Practical information for clinicians on selection and interpretation of different biomarker tests for Alzheimer disease:
practicalneurology.com/diseases-dia...
practicalneurology.com/diseases-dia...
Selection and Interpretation of Biomarker Tests for Alzheimer Disease
Diagnostic tests for Alzheimer disease can help guide clinical management, but results must be interpreted carefully.
practicalneurology.com
July 14, 2025 at 3:05 PM
Practical information for clinicians on selection and interpretation of different biomarker tests for Alzheimer disease:
practicalneurology.com/diseases-dia...
practicalneurology.com/diseases-dia...
Alzheimer's disease drug development pipeline: 2025 - Cummings - 2025 - Alzheimer's & Dementia: Translational Research & Clinical Interventions - Wiley Online Library alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
Alzheimer's disease drug development pipeline: 2025
Clinical trials for Alzheimer's disease (AD) must be registered on clinicaltrials.gov. The registry presents a variety of types of information related to the planned clinical trial. We assess clinic...
alz-journals.onlinelibrary.wiley.com
June 4, 2025 at 7:12 PM
Alzheimer's disease drug development pipeline: 2025 - Cummings - 2025 - Alzheimer's & Dementia: Translational Research & Clinical Interventions - Wiley Online Library alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
Reposted by Suzanne E. Schindler
From clinical trials to practice, WashU Medicine’s Memory Diagnostic Center offers top-tier, end-to-end Alzheimer's care. Now, a promising new study paves the way for clinics worldwide to adopt our elevated standard of outpatient care and infrastructure. 🔗 medicine.washu.edu/news/drug-to...
May 15, 2025 at 9:27 PM
From clinical trials to practice, WashU Medicine’s Memory Diagnostic Center offers top-tier, end-to-end Alzheimer's care. Now, a promising new study paves the way for clinics worldwide to adopt our elevated standard of outpatient care and infrastructure. 🔗 medicine.washu.edu/news/drug-to...
Development of Simple Risk Scores for Prediction of Brain β-Amyloid and Tau Status in Older Adults With Mild Cognitive Impairment: A Machine Learning Approach url:https://academic.oup.com/psychsocgerontology/article-abstract/doi/10.1093/geronb/gbaf085/8125623
May 25, 2025 at 5:31 PM
Development of Simple Risk Scores for Prediction of Brain β-Amyloid and Tau Status in Older Adults With Mild Cognitive Impairment: A Machine Learning Approach url:https://academic.oup.com/psychsocgerontology/article-abstract/doi/10.1093/geronb/gbaf085/8125623
Reposted by Suzanne E. Schindler
Reposted by Suzanne E. Schindler
Genetic studies reveal protective variants that delay Alzheimer's, offering insights into new therapies.
Be sure to check out our new review on protective genetic variants in Lancet Neurology, along with the editorial that features this research!
www.sciencedirect.com/science/arti...
Be sure to check out our new review on protective genetic variants in Lancet Neurology, along with the editorial that features this research!
www.sciencedirect.com/science/arti...
Protective genetic variants against Alzheimer's disease
Genetic studies can offer powerful insights for the development of disease-modifying therapies for Alzheimer's disease. Protective genetic variants th…
www.sciencedirect.com
May 21, 2025 at 2:20 PM
Genetic studies reveal protective variants that delay Alzheimer's, offering insights into new therapies.
Be sure to check out our new review on protective genetic variants in Lancet Neurology, along with the editorial that features this research!
www.sciencedirect.com/science/arti...
Be sure to check out our new review on protective genetic variants in Lancet Neurology, along with the editorial that features this research!
www.sciencedirect.com/science/arti...
Reposted by Suzanne E. Schindler
UPDATE: More than 5,000 homes were impacted, and 38 people were injured after an EF3 tornado tore across St. Louis. via @stlpublicradio.bsky.social
‘I just fell to my knees and cried’: St. Louisans face devastating damage after tornado that killed 5
More than 5,000 homes were impacted, and 38 people were injured after an EF3 tornado tore across St. Louis.
www.stlpr.org
May 18, 2025 at 2:37 PM
UPDATE: More than 5,000 homes were impacted, and 38 people were injured after an EF3 tornado tore across St. Louis. via @stlpublicradio.bsky.social
Reposted by Suzanne E. Schindler
❌ FALSE: “For 20 years…we were directing Alzheimer’s research to one hypothesis. And any other hypotheses were shut down.” - Sec. Kennedy
Over the last decade, less than 14% of new National Institutes of Health (NIH) Alzheimer’s projects focused on amyloid beta as the therapeutic target. 🧵(1/4)
Over the last decade, less than 14% of new National Institutes of Health (NIH) Alzheimer’s projects focused on amyloid beta as the therapeutic target. 🧵(1/4)
May 15, 2025 at 8:23 PM
❌ FALSE: “For 20 years…we were directing Alzheimer’s research to one hypothesis. And any other hypotheses were shut down.” - Sec. Kennedy
Over the last decade, less than 14% of new National Institutes of Health (NIH) Alzheimer’s projects focused on amyloid beta as the therapeutic target. 🧵(1/4)
Over the last decade, less than 14% of new National Institutes of Health (NIH) Alzheimer’s projects focused on amyloid beta as the therapeutic target. 🧵(1/4)
Reposted by Suzanne E. Schindler
The Wash U lecanemab paper is a hard act to follow. But here’s a combo experience with a private clinic and U Wash.
link.springer.com/article/10.1...
link.springer.com/article/10.1...
Monoclonal antibody administration in an academic institution and private neurological practice: a tale of two clinics - Journal of Neurology
The emergence of monoclonal antibody (MABs) drugs since the FDA approval of lecanemab has resulted in dramatic changes in the clinical approach and management of early-stage Alzheimer’s disease (AD). ...
link.springer.com
May 14, 2025 at 12:03 PM
The Wash U lecanemab paper is a hard act to follow. But here’s a combo experience with a private clinic and U Wash.
link.springer.com/article/10.1...
link.springer.com/article/10.1...
We have been trying to learn everything we can from our experiences with amyloid-targeting treatments to improve patient care. We present the findings from our first 234 patients treated with lecanemab in JAMA Neurology: ja.ma/42TLKzx
#ENDALZ
@WashUNeurology
#ENDALZ
@WashUNeurology
May 12, 2025 at 4:57 PM
We have been trying to learn everything we can from our experiences with amyloid-targeting treatments to improve patient care. We present the findings from our first 234 patients treated with lecanemab in JAMA Neurology: ja.ma/42TLKzx
#ENDALZ
@WashUNeurology
#ENDALZ
@WashUNeurology
Check out a great podcast featuring Joe Therriault
explaining how to diagnose Alzheimer's disease by integrating the clinical impression with plasma biomarkers: pca.st/episode/b729...
He makes PPV/NPV so easy to understand!
From his recent paper:
rdcu.be/eldzt
explaining how to diagnose Alzheimer's disease by integrating the clinical impression with plasma biomarkers: pca.st/episode/b729...
He makes PPV/NPV so easy to understand!
From his recent paper:
rdcu.be/eldzt
Web Player - Pocket Casts
Listen to your favorite podcasts online, in your browser. Discover the world's most powerful podcast player.
pca.st
May 8, 2025 at 1:38 PM
Check out a great podcast featuring Joe Therriault
explaining how to diagnose Alzheimer's disease by integrating the clinical impression with plasma biomarkers: pca.st/episode/b729...
He makes PPV/NPV so easy to understand!
From his recent paper:
rdcu.be/eldzt
explaining how to diagnose Alzheimer's disease by integrating the clinical impression with plasma biomarkers: pca.st/episode/b729...
He makes PPV/NPV so easy to understand!
From his recent paper:
rdcu.be/eldzt
Reposted by Suzanne E. Schindler
Thank you @60minutes.bsky.social for giving the NIH freezes, termination, and proposed budget cuts the attention they deserve. ALL Americans, regardless of party, will feel this impact to their health far beyond one administration. www.cbsnews.com/video/nih-cu...
Federal cuts to National Institutes of Health could threaten medical progress
Former National Institutes of Health Director Dr. Francis Collins, who abruptly left his NIH research lab in February, fears aggressive downsizing could impact Americans’ health.
www.cbsnews.com
April 28, 2025 at 12:16 PM
Thank you @60minutes.bsky.social for giving the NIH freezes, termination, and proposed budget cuts the attention they deserve. ALL Americans, regardless of party, will feel this impact to their health far beyond one administration. www.cbsnews.com/video/nih-cu...
Reposted by Suzanne E. Schindler
Reposted by Suzanne E. Schindler
Happy to share the work of Vincent Bouteloup, which has just been published in JAMA Neurology and presented this morning at the AD/PD Conference! jamanetwork.com/journals/jam...
Cognitive Phenotyping and Interpretation of Alzheimer Blood Biomarkers
This cohort study investigates if the clinical phenotype of patients without dementia is associated with blood phosphorylated tau 217 interpretation.
jamanetwork.com
April 4, 2025 at 11:13 AM
Happy to share the work of Vincent Bouteloup, which has just been published in JAMA Neurology and presented this morning at the AD/PD Conference! jamanetwork.com/journals/jam...
Reposted by Suzanne E. Schindler
Big loss today. Alzheon overall trial was negative. But there were provocative findings. www.neurologylive.com/view/valiltr...
Valiltramiprosate Demonstrates Greater Promise in Milder Forms of Alzheimer Disease, Phase 3 APOLLOE4 Study Shows
Although valiltramiprosate failed to distinguish itself from placebo on the primary end point, the drug performed significantly better among mild MCI participants vs those with mild Alzheimer disease.
www.neurologylive.com
April 2, 2025 at 2:46 AM
Big loss today. Alzheon overall trial was negative. But there were provocative findings. www.neurologylive.com/view/valiltr...